Health Kick Podcast: Neurizon’s ALS push and trial plans

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn about the company’s research on motor neurone disease and its drug development of NUZ-001 to treat ALS.

NUZ-001 is developed from monepantel, a drug which originated in veterinary practise as a drench for the treatment and control of gastrointestinal roundworms in sheep.

ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Neurizon has now developed a liquid formulation of NUZ-001 to improve patient access and experience.

Tune into the podcast to hear more.

This podcast was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.